Improving the ability to predict the efficacy of

Lung cancer is one of the most common cancers worldwide and is often fatal. But immunotherapies have changed the treatment of the disease showing encouraging findings for affected patients. At Tübingen University Hospital, a preclinical study led by Dr. Clemens Hinterleitner and Prof. Dr. Lars Zender, Medical Director of #Medical #Oncology and Pneumology, led to extremely promising results. The research group was able to develop a new methodology that makes it possible to better predict the likelihood of success of immunotherapies for lung cancer.

The video explains the new approach which is based on a #blood test rather than using a tissue sample of the #tumor prior to the cancer treatment of the patient. The blood patelets, the #thrombocytes, play an important role and may guide the way to a gentle and cost-effective alternative approach since there is still no reliable method to predict which patients willrespond to #immunotherapy. Moreover, not every patient responds equally well to the therapy, undesirable side effects can occur, and immunotherapy is extremely cost-intensive.Both #scientists are part of the Tübingen Cluster of Excellence #iFIT "Image-guided and Functionally Instructed Tumor Therapies" a unique research consortium combining three research areas to significally improve cancer treatment.

More on the Cluster: https://www.medizin.uni-tuebingen.de/...

Check out the study: https://www.nature.com/articles/s4146...


🎥 http://sciencerelations.de/